This startup develops immunotherapies for livestock and companion animals, focusing on sustainable and ethical solutions for animal health. Their products aim to improve animal well-being and support responsible animal care practices.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods of livestock management, such as surgical castration of piglets, raise ethical concerns regarding animal welfare and can negatively impact consumer perception of farming practices. Traditional methods may also involve the use of antibiotics, contributing to the growing problem of antimicrobial resistance.
Solution
BioAZ develops innovative immunotherapies designed to improve animal health and well-being while promoting sustainable and ethical animal care. Their lead product is an alternative to surgical castration in piglets, utilizing an immunocastration approach to reduce boar taint without the need for physical intervention. This technology offers a practical and cost-effective solution for farmers seeking to meet consumer demands for higher welfare standards and reduce reliance on traditional methods. BioAZ's immunotherapies are designed to be easy to administer, safe for both animals and users, and environmentally conscious, aligning with the principles of agroecological transition and the "One Health" concept.
Target Audience
The primary target audience includes livestock farmers, particularly pig farmers, seeking ethical and sustainable alternatives to traditional castration methods, as well as veterinary pharmaceutical companies looking to expand their product offerings with innovative animal health solutions.
Features
- Immunocastration technology for piglets, providing an alternative to surgical castration
- Focus on reducing boar taint and improving meat quality
- Development of easy-to-use and cost-effective immunotherapy solutions
- Emphasis on animal welfare and sustainable farming practices
- Designed to minimize the need for antibiotics in livestock management
- Solutions tailored to meet the practical and economic constraints of the veterinary pharmaceutical industry